Click here to get full coverage on New Analyst Forecast: $CNTX Given 'Buy' Rating - Quiver Quantitative

New Analyst Forecast: $CNTX Given 'Buy' Rating  Quiver Quantitative

New Analyst Forecast: $CNTX Given 'Buy' Rating - Quiver Quantitative

Click here to get full coverage on D. Boral Capital Maintains Context Therapeutics (CNTX) Buy Recommendation - Nasdaq

D. Boral Capital Maintains Context Therapeutics (CNTX) Buy Recommendation  Nasdaq

D. Boral Capital Maintains Context Therapeutics (CNTX) Buy Recommendation - Nasdaq

Click here to get full coverage on Earnings Report: Why CNTX stock could rally in 2025 - July 2025 Gainers & Real-Time Chart Pattern Alerts - moha.gov.vn

Earnings Report: Why CNTX stock could rally in 2025 - July 2025 Gainers & Real-Time Chart Pattern Alerts  moha.gov.vn

Earnings Report: Why CNTX stock could rally in 2025 - July 2025 Gainers & Real-Time Chart Pattern Alerts - moha.gov.vn

Click here to get full coverage on Is Context Therapeutics (NASDAQ:CNTX) In A Good Position To Invest In Growth? - Yahoo Finance

Is Context Therapeutics (NASDAQ:CNTX) In A Good Position To Invest In Growth?  Yahoo Finance

Is Context Therapeutics (NASDAQ:CNTX) In A Good Position To Invest In Growth? - Yahoo Finance

Click here to get full coverage on Context Therapeutics (NASDAQ: CNTX) Highlights CT-95 and CT-202 at SITC Meeting - Stock Titan

Context Therapeutics (NASDAQ: CNTX) Highlights CT-95 and CT-202 at SITC Meeting  Stock Titan

Context Therapeutics (NASDAQ: CNTX) Highlights CT-95 and CT-202 at SITC Meeting - Stock Titan

Click here to get full coverage on Context Therapeutics: Undervalued Cancer Fighter (NASDAQ:CNTX) - Seeking Alpha

Context Therapeutics: Undervalued Cancer Fighter (NASDAQ:CNTX)  Seeking Alpha

Context Therapeutics: Undervalued Cancer Fighter (NASDAQ:CNTX) - Seeking Alpha

Click here to get full coverage on Here's Why We're Not Too Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn Situation - simplywall.st

Here's Why We're Not Too Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn Situation  simplywall.st

Here's Why We're Not Too Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn Situation - simplywall.st

Click here to get full coverage on Guggenheim Initiates Coverage of Context Therapeutics (CNTX) with Buy Recommendation - Nasdaq

Guggenheim Initiates Coverage of Context Therapeutics (CNTX) with Buy Recommendation  Nasdaq

Guggenheim Initiates Coverage of Context Therapeutics (CNTX) with Buy Recommendation - Nasdaq

Click here to get full coverage on Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results - GlobeNewswire

Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results  GlobeNewswire

Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results - GlobeNewswire

Click here to get full coverage on Context Therapeutics Regains Nasdaq Compliance - TradingView — Track All Markets

Context Therapeutics Regains Nasdaq Compliance  TradingView — Track All Markets

Context Therapeutics Regains Nasdaq Compliance - TradingView — Track All Markets

Click here to get full coverage on This Synopsys Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday - Benzinga

This Synopsys Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday  Benzinga

This Synopsys Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday - Benzinga

Click here to get full coverage on Forecast Cut: Can CNTX stock surprise with earnings upside - Weekly Investment Report & Community Driven Trade Alerts - moha.gov.vn

Forecast Cut: Can CNTX stock surprise with earnings upside - Weekly Investment Report & Community Driven Trade Alerts  moha.gov.vn

Forecast Cut: Can CNTX stock surprise with earnings upside - Weekly Investment Report & Community Driven Trade Alerts - moha.gov.vn

Click here to get full coverage on Context Therapeutics Gains 11%, Insider Trades Reap Benefit - simplywall.st

Context Therapeutics Gains 11%, Insider Trades Reap Benefit  simplywall.st

Context Therapeutics Gains 11%, Insider Trades Reap Benefit - simplywall.st

Click here to get full coverage on Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting - GlobeNewswire

Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting  GlobeNewswire

Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting - GlobeNewswire

Click here to get full coverage on Context Therapeutics (NASDAQ: CNTX) to join Guggenheim and Stifel investor conferences - Stock Titan

Context Therapeutics (NASDAQ: CNTX) to join Guggenheim and Stifel investor conferences  Stock Titan

Context Therapeutics (NASDAQ: CNTX) to join Guggenheim and Stifel investor conferences - Stock Titan

Click here to get full coverage on Rare Stock Picks In June 2025 - From 26 Discerning Analysts - Seeking Alpha

Rare Stock Picks In June 2025 - From 26 Discerning Analysts  Seeking Alpha

Rare Stock Picks In June 2025 - From 26 Discerning Analysts - Seeking Alpha

Click here to get full coverage on Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results - GlobeNewswire

Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results  GlobeNewswire

Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results - GlobeNewswire

Click here to get full coverage on Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer - GlobeNewswire

Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer  GlobeNewswire

Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer - GlobeNewswire

Click here to get full coverage on Centrexion Therapeutics stock hits 52-week low at $0.55 - Investing.com

Centrexion Therapeutics stock hits 52-week low at $0.55  Investing.com

Centrexion Therapeutics stock hits 52-week low at $0.55 - Investing.com

Click here to get full coverage on Centrexions’ CNTX-4975 LoA in osteoarthritis-related knee pain raises by 5 - Clinical Trials Arena

Centrexions’ CNTX-4975 LoA in osteoarthritis-related knee pain raises by 5  Clinical Trials Arena

Centrexions’ CNTX-4975 LoA in osteoarthritis-related knee pain raises by 5 - Clinical Trials Arena

Click here to get full coverage on Context Therapeutics Presents CTIM-76 Phase 1 Trial in Progress at ASCO 2025 - Yahoo Finance

Context Therapeutics Presents CTIM-76 Phase 1 Trial in Progress at ASCO 2025  Yahoo Finance

Context Therapeutics Presents CTIM-76 Phase 1 Trial in Progress at ASCO 2025 - Yahoo Finance

Click here to get full coverage on Context Therapeutics (CNTX) Stock Price, News & Analysis - MarketBeat

Context Therapeutics (CNTX) Stock Price, News & Analysis  MarketBeat

Context Therapeutics (CNTX) Stock Price, News & Analysis - MarketBeat

Click here to get full coverage on CNTX Stock Price and Chart — NASDAQ:CNTX - TradingView — Track All Markets

CNTX Stock Price and Chart — NASDAQ:CNTX  TradingView — Track All Markets

CNTX Stock Price and Chart — NASDAQ:CNTX - TradingView — Track All Markets

Click here to get full coverage on Intra-Articular CNTX-4975 Improves Pain in Knee Osteoarthritis - Rheumatology Advisor

Intra-Articular CNTX-4975 Improves Pain in Knee Osteoarthritis  Rheumatology Advisor

Intra-Articular CNTX-4975 Improves Pain in Knee Osteoarthritis - Rheumatology Advisor

Click here to get full coverage on MPM BIOIMPACT LLC Acquires Significant Stake in Context Therapeu - GuruFocus

MPM BIOIMPACT LLC Acquires Significant Stake in Context Therapeu  GuruFocus

MPM BIOIMPACT LLC Acquires Significant Stake in Context Therapeu - GuruFocus

Click here to get full coverage on Context Therapeutics Announces $100 Million Private Placement - Yahoo Finance

Context Therapeutics Announces $100 Million Private Placement  Yahoo Finance

Context Therapeutics Announces $100 Million Private Placement - Yahoo Finance

Click here to get full coverage on CNTX IPO News - Non-opioid pain therapy developer Centrexion Therapeutics withdraws $75 million IPO - renaissancecapital.com

CNTX IPO News - Non-opioid pain therapy developer Centrexion Therapeutics withdraws $75 million IPO  renaissancecapital.com

CNTX IPO News - Non-opioid pain therapy developer Centrexion Therapeutics withdraws $75 million IPO - renaissancecapital.com

Click here to get full coverage on Capsaicin Injections May Relieve Osteoarthritis Knee Pain - CreakyJoints

Capsaicin Injections May Relieve Osteoarthritis Knee Pain  CreakyJoints

Capsaicin Injections May Relieve Osteoarthritis Knee Pain - CreakyJoints

Click here to get full coverage on Eli Lilly In-Licenses Non-Opioid Drug from Centrexion in $997 Million-Plus Deal - BioSpace

Eli Lilly In-Licenses Non-Opioid Drug from Centrexion in $997 Million-Plus Deal  BioSpace

Eli Lilly In-Licenses Non-Opioid Drug from Centrexion in $997 Million-Plus Deal - BioSpace

Click here to get full coverage on Centrexion farms out pain drug to Lilly for $47.5M and could reap much more - Fierce Biotech

Centrexion farms out pain drug to Lilly for $47.5M and could reap much more  Fierce Biotech

Centrexion farms out pain drug to Lilly for $47.5M and could reap much more - Fierce Biotech

Click here to get full coverage on CNTX IPO News - Centrexion Therapeutics postpones $75 million IPO - renaissancecapital.com

CNTX IPO News - Centrexion Therapeutics postpones $75 million IPO  renaissancecapital.com

CNTX IPO News - Centrexion Therapeutics postpones $75 million IPO - renaissancecapital.com

Click here to get full coverage on CNTX IPO News - Ex-Pfizer CEO's pain biotech Centrexion Therapeutics sets terms for $75 million IPO - renaissancecapital.com

CNTX IPO News - Ex-Pfizer CEO's pain biotech Centrexion Therapeutics sets terms for $75 million IPO  renaissancecapital.com

CNTX IPO News - Ex-Pfizer CEO's pain biotech Centrexion Therapeutics sets terms for $75 million IPO - renaissancecapital.com

Click here to get full coverage on The 100%+ Club: Piper Sandler’s 3 Top Picks for Triple-Digit Gains - Yahoo Finance

The 100%+ Club: Piper Sandler’s 3 Top Picks for Triple-Digit Gains  Yahoo Finance

The 100%+ Club: Piper Sandler’s 3 Top Picks for Triple-Digit Gains - Yahoo Finance

Click here to get full coverage on Former Pfizer CEO's Boston Startup Centrexion Lands $67M for Ph3 Osteoarthritis Pain Drug - BioSpace

Former Pfizer CEO's Boston Startup Centrexion Lands $67M for Ph3 Osteoarthritis Pain Drug  BioSpace

Former Pfizer CEO's Boston Startup Centrexion Lands $67M for Ph3 Osteoarthritis Pain Drug - BioSpace

Click here to get full coverage on CNTX wins 19th all India BSNL cricket tournament - Times of India

CNTX wins 19th all India BSNL cricket tournament  Times of India

CNTX wins 19th all India BSNL cricket tournament - Times of India

Click here to get full coverage on Context Therapeutics Inc. (NASDAQ:CNTX) Receives $5.40 Average Target Price from Brokerages - Defense World

Context Therapeutics Inc. (NASDAQ:CNTX) Receives $5.40 Average Target Price from Brokerages  Defense World

CNTX

Price Chart

Key Statistics

Technicals

About CNTX

Latest News

New Analyst Forecast: $CNTX Given 'Buy' Rating - Quiver Quantitative

D. Boral Capital Maintains Context Therapeutics (CNTX) Buy Recommendation - Nasdaq

Earnings Report: Why CNTX stock could rally in 2025 - July 2025 Gainers & Real-Time Chart Pattern Alerts - moha.gov.vn

Advanced Charts

Top Gainers

Top Losers